Compare GF & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | TMCI |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 174.6M |
| IPO Year | N/A | 2021 |
| Metric | GF | TMCI |
|---|---|---|
| Price | $11.89 | $2.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.21 |
| AVG Volume (30 Days) | 28.1K | ★ 629.2K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,879,000.00 |
| Revenue This Year | N/A | $3.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.90 |
| 52 Week Low | $7.38 | $2.07 |
| 52 Week High | $9.41 | $10.79 |
| Indicator | GF | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 27.86 |
| Support Level | $11.85 | $2.56 |
| Resistance Level | $12.34 | $2.42 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 35.13 | 12.93 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.